Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trials in Nashville, Tennessee

4 studies are recruiting for recurrent head and neck squamous cell carcinoma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

   This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head …

   Stage

   Phase 2

   Ages

   18 to 79

   Site

   Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

   Locations

   178 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04671667 on ClinicalTrials.gov

2. FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

   Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, r…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Site#0126, Nashville, Tennessee

   Locations

   203 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT06788990 on ClinicalTrials.gov

3. Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

   This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the primary tumor (sentinel lymph nodes) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing surgery. Th…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT05901545 on ClinicalTrials.gov

4. Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

   This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT05945875 on ClinicalTrials.gov